Loïc Epelboin1,2, Jérôme Robert3,4,5, Ellina Tsyrina-Kouyoumdjian1, Sonia Laouira5, Vanina Meyssonnier1, Eric Caumes1,2. 1. Infectious and Tropical Diseases Department, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Paris, France. 2. Sorbonne Universités, UPMC Univ Paris, Paris, France. 3. Department of Bacteriology and Hygiene, Sorbonne Universités, Paris, France. 4. Centre d'Immunologie et des Maladies Infectieuses, CIMI, team E13 (Bacteriology), Paris, France. 5. INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI, team E13 (Bacteriology), Paris, France.
Abstract
BACKGROUND: Carriage of and infection with multidrug-resistant Gram-negative bacilli (MDR-GNB) are a potential cause of concern in travelers with no history of hospitalization abroad. METHODS: All consecutive returning travelers hospitalized in our department between February 2012 and January 2013 were prospectively screened for MDR-GNB gastrointestinal tract carriage or infection. We compared the prevalence of MDR-GNB in travelers to a non-travelers nonexposed group. Then among the travelers, MDR-GNB carriers were compared to noncarriers to determine risk factors of acquisition of MDR-GNB. RESULTS: Overall, 359 patients (191 travelers, 168 non-travelers) were included, and 25 (6.4%), including 23 travelers, harbored MDR-GNB. Five travelers had an MDR-GNB infection while 18 were asymptomatic enteric carriers. MDR-GNB carriage or infection was significantly more frequent in travelers (11.0% vs 1.2% for non-travelers, odds ratio (OR) = 11.3, p < 0.001) and in patients born outside France (OR = 1.67; p = 0.03). Among travelers, in multivariate analysis, factors independently associated with MDR-GNB carriage or infection were traveling to Asia (OR = 3.1; p = 0.01) and visiting friends and relatives (VFR) or migrants (OR=3.6; p = 0.01). CONCLUSIONS: The 10-fold higher prevalence rate of MDR-GNB in travelers raises the issues of systematic screening of all travelers, and of the choice of first line antibiotic therapy when treating urinary tract infections in travelers, especially those VFR, migrants, and those returning from Asia.
BACKGROUND: Carriage of and infection with multidrug-resistant Gram-negative bacilli (MDR-GNB) are a potential cause of concern in travelers with no history of hospitalization abroad. METHODS: All consecutive returning travelers hospitalized in our department between February 2012 and January 2013 were prospectively screened for MDR-GNB gastrointestinal tract carriage or infection. We compared the prevalence of MDR-GNB in travelers to a non-travelers nonexposed group. Then among the travelers, MDR-GNB carriers were compared to noncarriers to determine risk factors of acquisition of MDR-GNB. RESULTS: Overall, 359 patients (191 travelers, 168 non-travelers) were included, and 25 (6.4%), including 23 travelers, harbored MDR-GNB. Five travelers had an MDR-GNB infection while 18 were asymptomatic enteric carriers. MDR-GNB carriage or infection was significantly more frequent in travelers (11.0% vs 1.2% for non-travelers, odds ratio (OR) = 11.3, p < 0.001) and in patients born outside France (OR = 1.67; p = 0.03). Among travelers, in multivariate analysis, factors independently associated with MDR-GNB carriage or infection were traveling to Asia (OR = 3.1; p = 0.01) and visiting friends and relatives (VFR) or migrants (OR=3.6; p = 0.01). CONCLUSIONS: The 10-fold higher prevalence rate of MDR-GNB in travelers raises the issues of systematic screening of all travelers, and of the choice of first line antibiotic therapy when treating urinary tract infections in travelers, especially those VFR, migrants, and those returning from Asia.
Authors: Lin H Chen; Pauline V Han; Mary E Wilson; Rhett J Stoney; Emily S Jentes; Christine Benoit; Winnie W Ooi; Elizabeth D Barnett; Davidson H Hamer Journal: Travel Med Infect Dis Date: 2016-10-02 Impact factor: 6.211
Authors: Mark S Riddle; Bradley A Connor; Nicholas J Beeching; Herbert L DuPont; Davidson H Hamer; Phyllis Kozarsky; Michael Libman; Robert Steffen; David Taylor; David R Tribble; Jordi Vila; Philipp Zanger; Charles D Ericsson Journal: J Travel Med Date: 2017-04-01 Impact factor: 8.490
Authors: Cliodna A M McNulty; Donna M Lecky; Li Xu-McCrae; Deborah Nakiboneka-Ssenabulya; Keun-Taik Chung; Tom Nichols; Helen Lucy Thomas; Mike Thomas; Adela Alvarez-Buylla; Kim Turner; Sahida Shabir; Susan Manzoor; Stephen Smith; Linda Crocker; Peter M Hawkey Journal: J Antimicrob Chemother Date: 2018-05-01 Impact factor: 5.790
Authors: Dana M Blyth; Katrin Mende; Ashley M Maranich; Miriam L Beckius; Kristie A Harnisch; Crystal A Rosemann; Wendy C Zera; Clinton K Murray; Kevin S Akers Journal: Trop Dis Travel Med Vaccines Date: 2016-03-14